{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(9)"],"submitter":["Vogel B"],"pubmed_abstract":["<h4>Importance</h4>Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor monotherapy reduces bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).<h4>Objective</h4>To explore sex differences and evaluate the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin.<h4>Design, setting, and participants</h4>This was a prespecified secondary analysis of TWILIGHT, an investigator-initiated, placebo-controlled randomized clinical trial conducted at 187 sites across 11 countries. Study participants included patients who underwent successful PCI with drug-eluting stents, were planned for discharge with ticagrelor plus aspirin, and who had at least 1 clinical and at least 1 angiogr"],"journal":["JAMA cardiology"],"pagination":["1032-1041"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8124295"],"repository":["biostudies-literature"],"pubmed_title":["Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial."],"pmcid":["PMC8124295"],"pubmed_authors":["Witzenbichler B","Gil R","Kunadian V","Pocock S","Kaul U","Farhan S","Collier T","Huber K","Goel R","Sardella G","Mehta SR","Briguori C","Gibson CM","Mehran R","Dudek D","Sartori S","Sharma SK","Kornowski R","Moliterno D","Ohman EM","Vogel B","Escaned J","Baber U","Angiolillo DJ","Zhang Z","Dangas G","Krucoff MW","Han YL","Cohen DJ"],"additional_accession":[]},"is_claimable":false,"name":"Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.","description":"<h4>Importance</h4>Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor monotherapy reduces bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).<h4>Objective</h4>To explore sex differences and evaluate the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin.<h4>Design, setting, and participants</h4>This was a prespecified secondary analysis of TWILIGHT, an investigator-initiated, placebo-controlled randomized clinical trial conducted at 187 sites across 11 countries. Study participants included patients who underwent successful PCI with drug-eluting stents, were planned for discharge with ticagrelor plus aspirin, and who had at least 1 clinical and at least 1 angiogr","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-05-09T04:12:06.248Z","creation":"2024-11-20T17:22:25.783Z"},"accession":"S-EPMC8124295","cross_references":{"pubmed":["33991416"],"doi":["10.1001/jamacardio.2021.1720"]}}